Development of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatment

Paul Derose, Philip E. Thorpe, David E. Gerber

Research output: Contribution to journalArticle

42 Scopus citations

Abstract

Bavituximab is a chimeric monoclonal antibody directed against the membrane phospholipid phosphatidylserine. Phosphatidylserine exposure is increased on endothelial cells and apoptotic cancer cells in solid tumors, allowing tumor-specific targeting of bavituximab. Bavituximab binding results in tumor vessel occlusion and enhanced antitumor immunity. Preclinical investigations have demonstrated efficacy as monotherapy and in combination with other modalities against multiple cancer types. Phase I clinical trials of bavituximab monotherapy and in combination with chemotherapy in adults with refractory solid tumors have been completed. Phase II trials of bavituximab in combination with chemotherapy for the first- and second-line treatment of advanced non-small-cell lung cancer are currently ongoing. This article summarizes the preclinical development and clinical experience with bavituximab in non-small-cell lung cancer.

Original languageEnglish (US)
Pages (from-to)933-944
Number of pages12
JournalImmunotherapy
Volume3
Issue number8
DOIs
StatePublished - Aug 1 2011

Keywords

  • bavituximab
  • monoclonal antibody
  • non-small-cell lung cancer
  • targeted therapy
  • vascular disrupting agent
  • vascular targeting agent

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint Dive into the research topics of 'Development of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatment'. Together they form a unique fingerprint.

  • Cite this